Quantcast
Last updated on April 16, 2014 at 14:42 EDT

Latest Lausanne Stories

2009-09-03 10:00:00

LAUSANNE, Switzerland, September 3 /PRNewswire/ -- Debiopharm Group, SA (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, today presented the 'Debiopharm Life Sciences Award' to Dr Lluis Quintana-Murci from the Institut Pasteur in France, for his outstanding innovative research in the emerging field of evolutionary genetics of infection. Funded by Debiopharm, the ceremony took...

2009-07-21 04:18:00

LAUSANNE, Switzerland, July 21 /PRNewswire/ -- Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, today announced that the Swiss agency for therapeutic products, Swissmedic, has issued a marketing authorisation for Moapar(R) 11.25mg, the first 3-month injectable formulation, prescribed for a reversible reduction of serum testosterone to the level of castration in...

2009-06-23 04:48:00

LAUSANNE, Switzerland, June 23 /PRNewswire/ -- Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, announced that Salvacyl(R) (also known under the trade names Moapar(R) and Salvapar(R)), was launched in Germany in May 2009, by Dr R. Pfleger GmbH. In April 2009, Salvacyl(R) was also launched on a preliminary basis in Belgium. The effective commercial launch will take...

721bf686865327d446596d0a758d2d111
2009-06-17 10:23:06

Representatives from the four cities vying to become the host site for the 2016 Olympics gave presentations Wednesday to the International Olympic Committee. Chicago, Madrid, Rio de Janeiro and Tokyo are the finalists for the 2016 Games. Sessions Wednesday and Thursday in Lausanne, Switzerland, are part of the IOC's assessment process that will end with a vote Oct. 2 to choose the Olympic site. All 93 IOC members attended the meetings in Switzerland where the candidate cities' representatives...

2009-05-05 13:09:00

First Shareholder Meeting Since Split Draws Global Protest NEW YORK, May 5 /PRNewswire-USNewswire/ -- With global tobacco deaths climbing above 5.4 million a year, Philip Morris International (PMI) is heralding a 12.7 percent net revenue growth in 2008. Not coincidentally the regions most impacted by the tobacco epidemic are the same "emerging markets" that the corporation credits with driving its growth. But at the end of PMI's 2008 surge, the international community moved to put a damper...

2009-04-30 04:05:00

LAUSANNE, Switzerland, April 30 /PRNewswire/ -- Debiopharm Group (Debiopharm), a global biopharmaceutical development specialist that focuses on serious medical conditions, particularly in the field of oncology, announced that on April 7, 2009 the last patient was randomised to take part in a phase IIb clinical study with Debio 025, a selective cyclophilin (Cyp) inhibitor with a potent anti-hepatitis C (HCV) effect. In a record time of three months, a total of 290 patients were randomised...

2009-04-23 18:12:00

World Malaria Day Events Held in Nairobi, London, Washington LAUSANNE, Switzerland, April 23 /PRNewswire/ -- To honor the theme for World Malaria Day on 4/25, 'Counting Malaria Out,' Vestergaard Frandsen is stepping up production of its best selling bed net, called PermaNet(R), and introducing a new version that is effective against insecticide resistant mosquitoes. Malaria claims more than one million lives every year, and leaves half of the world's population at risk of contracting the...

2009-02-03 09:08:55

1 step closer to personalized medicineResearchers at the Swiss Institute of Bioinformatics and the Swiss National Center of Competence in Research in Molecular Oncology in Lausanne have developed a new test to predict how breast cancer patients respond to chemotherapy, which could help change how treatment is delivered in the future. In an article, 'A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer' i, published in Nature Medicine, Dr Pierre...

2008-12-10 00:52:00

LAUSANNE, Switzerland, December 10 /PRNewswire/ -- Diagnoplex, a developer of molecular cancer diagnostics today announced the closing of a Series A financing raising CHF10 million ($8.3 million). The A-round was led by Novartis Venture Fund and NeoMed, with Initiative Capital Romandie acting as co-investor. The Novartis Venture Fund was also a seed investor in the company. BCCC Avocats acted as counsel to the investors and BMP Associés acted...

2008-11-04 12:00:26

LAUSANNE, Switzerland, November 4 /PRNewswire/ -- Debiopharm Group (Debiopharm), a global biopharmaceutical development specialist that focuses on serious medical conditions and particularly oncology, announced today that Debiovision Inc., its Canadian affiliate, filed its Complete Response to the approvable letter received from the United States (U.S.) Food and Drug Administration (FDA) for Sanvar(R), or Debio 8609 (vapreotide acetate). The immediate release formulation of Sanvar(R), a...